BioPharma Resources

Investigational drug · Phase 3

Efimosfermin

Also called: BOS-580

Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

7

6 still active

All registered trials

9

Any phase or sponsor naming "Efimosfermin"

First trial start

2021

Sep 30, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Efimosfermin", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Non-alcoholic Fatty Liver Disease
  • Metabolic Dysfunction-associated Steatohepatitis
  • Liver Diseases, Alcoholic
  • Metabolic Dysfunction-Associated Steatohepatitis
  • Nonalcoholic Steatohepatitis (NASH)

Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Efimosfermin" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 12 on PubMed

Also in development for Non-alcoholic Fatty Liver Disease

  • GSK4532990Phase 23 trials

    GSK · Non-alcoholic Fatty Liver Disease, Liver Diseases, Alcoholic, Nonalcoholic Fatty Liver Disease

  • EfinopegdutideMK-6024, HM12525APhase 22 trials

    Merck & Co. · Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic

  • HU6Phase 22 trials

    Rivus Pharmaceuticals, Inc. · Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver

  • MN-001Phase 21 trial

    MediciNova · Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.